Afterwards, better results were obtained using other ALK inhibitor compounds, alone or in combination with chemotherapy, in solid tumors such as lung cancer, but some problems emerged due to secondary mutation and amplification of ALK and off-target mechanisms including activation of ‘bypass’ signaling pathways [62,63,64]. The gene discussed is ALK; the disease is lung cancer.